Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial
25 octubre, 2024
Dra. Joana Vitalle Andrade
Instituto de Biomedicinade Sevilla(IBiS)
Hospital Universitario Virgen del Rocio
